JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-1
Phase of Trial: Phase IV
Latest Information Update: 05 Jun 2015
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Pharmacodynamics
- Acronyms STRATIFY-1
- Sponsors Biogen Idec
- 06 Mar 2013 Results presented at the 65th American Academy of Neurology Annual Meeting, according to a Biogen Idec media release.
- 30 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Mar 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.